Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-64: 64Cu-ATSM Safety and Dosing in Malignant Brain Tumors
jRCT2091220362Phase 1Completed
- Sponsor
- Hiroaki Kurihara
- Start
- Jul 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 1, open-label trial of copper-64-diacetyl-bis(N4-methylthiosemicarbazone) in glioblastoma (GBM), glioma, primary central nervous system lymphoma (PCNSL) and 2 more (2 cohorts), sponsored by Hiroaki Kurihara. Primary endpoint: Dose-limiting toxicity incidence. Started Jul 2018; status: completed.
02
Drugs
copper-64-diacetyl-bis(N4-methylthiosemicarbazone)
03
Conditions
glioblastoma (GBM)gliomaprimary central nervous system lymphoma (PCNSL)meningiomabrain metastases
Beyond the preview
Go deeper on jRCT2091220362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220362.